$EXAM (ExamWorks Group, Inc.)

$EXAM {{ '2016-07-27T17:22:34+0000' | timeago}} • Announcement

$EXAM announced the successful completion of its acquisition by an affiliate of Leonard Green & Partners. Each share of $EXAM was converted into right to receive $35.05 per share in cash. Also, $EXAM has become an indirect subsidiary of affiliates of Leonard. $EXAM common stock ceased trading on NYSE at close of market on July 27.

$CELG {{ '2017-10-20T12:40:12+0000' | timeago}} • Announcement

$CELG disclosed in an SEC filing that it expects to incur a pretax charge to earnings for 4Q17 in the range of $300-500MM ($0.27-0.45 per diluted share after tax) in connection with its decision to stop the two trials for Crohn's disease. Celgene also added that it would require to pay half of this charge in cash.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$CELG {{ '2017-10-19T21:12:44+0000' | timeago}} • Announcement

$CELG said that it will stop the two trials for treating the Crohn's disease (a chronic inflammatory bowel disease), following an recommendation of the Data Monitoring Committee. No safety signals were identified during a recent interim futility analysis. Celgene added that the third trial will not be initiated at this time.

$CVS {{ '2017-10-18T15:07:12+0000' | timeago}} • Announcement

$CVS signed a five-year agreement with $ANTM to provide services to support  IngenioRx, effective Jan 1, 2020. Based on this CVS Caremark will manage certain services for IngenioRx.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$AGN {{ '2017-10-02T17:04:07+0000' | timeago}} • Announcement

FDA accepts to do a priority review of $AGN's antibiotic drug Avycaz. The supplemental New Drug Application (sNDA) filed by Allergan seeks to expand the usage of Avycaz for the treatment of patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. The FDA is expected to take action on the filing in 1Q18.

$PRSC {{ '2017-09-29T14:57:13+0000' | timeago}} • Announcement

$PRSC completed the sale of Mission Providence Pty Ltd to Konekt Limited for approx. US$22MM. Mission Providence was formed as a JV between $PRSC and Mission Australia. $PRSC received 75% of the total consideration for its ownership interest in the JV, which, after deducting transaction expenses, equated to about $16MM in net proceeds.

$RAD {{ '2017-09-28T12:58:37+0000' | timeago}} • Infographic

$RAD Rite Aid Corp. Earnings AlphaGraphics: Q2 2018 highlights

$RAD {{ '2017-09-28T11:32:28+0000' | timeago}} • Announcement

In 2Q18, $RAD opened 1 store, relocated 1 store, remodeled 54 stores and expanded 1 store, bringing the total number of wellness stores chainwide to 2,532. The company,  whose merger deal with $WBA was terminated, closed 17 stores, resulting in a total store count of 4,507 at the end of the second quarter.

$RAD {{ '2017-09-28T11:30:40+0000' | timeago}} • Announcement

Even as the revenue of drugstore chain $RAD for 2Q18 slipped 4.4% to $7.7Bil, net income surged more than 11 times to $170.7MM or $0.16 per diluted share, vs. last year’s $14.8MM or $0.01 a share. Operating results for the quarter improved majorly due to the $325MM merger termination fee from $WBA.

$AGN {{ '2017-09-25T15:26:35+0000' | timeago}} • Announcement

$AGN CFO Tessa Hilado has decided to retire from the company. Allergan has initiated a search to fill the position. Hilado, who joined the company in Dec 2014, will continue in her current role until a successor is named to ensure a smooth transition.

$AGN {{ '2017-09-25T12:23:08+0000' | timeago}} • Announcement

$AGN has authorized a new $2Bil share repurchase program, and has affirmed its commitment to increasing its regular quarterly cash dividend annually. The company also affirmed its 3Q17 revenue projection, which was issued on Aug 3, 2017.

$AGN {{ '2017-09-22T21:53:16+0000' | timeago}} • Announcement

$AGN received a Refusal to File letter from the US FDA on its Supplemental New Drug Application (sNDA) for Vraylar for treatment of negative symptoms associated with schizophrenia in adult patients. VRAYLAR is an oral antipsychotic approved in the US to treat schizophrenia. The FDA said the sNDA was not sufficient to permit a substantive review.

$AGN {{ '2017-09-22T14:30:34+0000' | timeago}} • Announcement

$AGN announced top-line results from new data for the Centaur Phase 2b study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. $AGN is currently enrolling patients in a 2,000 patient phase 3 clinical trial of CVC called the Aurora trial.

$CORE {{ '2017-09-21T13:02:10+0000' | timeago}} • Announcement

$CORE, marketers of fresh and broad-line supply solutions to convenience retail industry, has announced that it has renewed its 3-year supply chain agreement with $RAD. Core-Mark is currently providing service to approx 4,500 Rite Aid stores. Finer details of the agreement are under wraps.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

Recent Transcripts

RAD (Rite Aid Corporation)
Thursday, September 28 2017 - 12:30pm
PRSC (Providence Service Corp.)
Wednesday, August 9 2017 - 12:00pm
OMER (Omeros Corporation)
Tuesday, August 8 2017 - 8:30pm
CVS (CVS Health Corporation)
Tuesday, August 8 2017 - 12:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
LHCG (LHC Group, Inc.)
Thursday, August 3 2017 - 3:00pm
USPH (US Physical Therapy Inc.)
Thursday, August 3 2017 - 2:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
CHE (Chemed Corp.)
Wednesday, July 26 2017 - 2:00pm
PETS (PetMed Express, Inc.)
Monday, July 24 2017 - 12:30pm
USPH (US Physical Therapy Inc.)
Thursday, June 29 2017 - 2:30pm
OMER (Omeros Corporation)
Wednesday, May 10 2017 - 8:30pm
PMC (PharMerica Corporation)
Wednesday, May 10 2017 - 2:00pm
PRSC (Providence Service Corp.)
Wednesday, May 10 2017 - 12:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, May 8 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm

AlphaGraphics you may like